于本公告日期，认购人为公司的控股股东，因此为公司于上市规则项下的关联人士。 药明合联(02268)公布，于2025年9月3日(联交所交易时段前)，该公司与认购人药明生物(02269)订立认购 协议，拟向认购人发行2413.4万股认购股份，认购价为每股认购股份58.85港元(与配售价相同)，总代价 约为14.2亿港元。 认购事项净筹约14.14亿港元，约90%将用于进一步扩大集团的服务能力及产能，包括但不限于其生物 偶联药物、原料药及药品的临床及商业生产产能。约10%将用于集团的营运资金需求及一般公司用途。 ...

General Provisions - The company aims to protect the legal rights of the company, shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws and regulations [1][4] - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2] - The registered capital of the company is 70 million RMB [3] Business Objectives and Scope - The company's business objective is to establish a new operating mechanism through joint investment by shareholders and to promote the Xgimi brand globally [4][5] - The business scope includes software development, technical services, manufacturing of household appliances, and various sales and advertising activities [5] Shares - The company's shares are in the form of stocks, including domestic shares (A-shares) and overseas listed shares (H-shares) [7] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for each share of the same category [7][8] - The company has a total of 3,675,000 shares issued, with specific details on the shareholding structure provided [8] Shareholders and Shareholder Meetings - The company recognizes the rights of shareholders to receive dividends, participate in meetings, and supervise the company's operations [16][35] - Shareholders holding more than 10% of shares can request the board to convene a temporary shareholder meeting [30][31] - The company must provide adequate notice for shareholder meetings, including details on the agenda and voting procedures [62][64] Board of Directors and Management - The board of directors is responsible for the overall governance of the company, including the appointment of senior management [19][22] - The company has established an audit committee to oversee financial practices and ensure compliance with regulations [19] Financial Accounting and Auditing - The company is required to maintain a financial accounting system and conduct regular audits to ensure transparency and accountability [4][19] - Profit distribution and financial responsibilities are clearly defined within the company's articles of association [4][19] Amendments to Articles of Association - The articles of association can be amended following the procedures outlined in the document, requiring approval from the shareholders [10][26]

格隆汇8月28日丨中国金石(01380.HK)发布公告，2025年8月28日，公司(作为发行人)与刘德生(作为认购 人)订立另一份认购协议，据此，公司有条件同意配发及发行，而认购人有条件同意认购1123.6万股认 购股份，认购价为每股认购股份0.178港元，代价为200万港元。 认购股份合共相当于：(a)于本公告日期现有已发行股份约3.03%；及(b)紧随完成后经配发及发行认购股 份扩大的已发行股份约2.94%。发行认购股份将根据拟于股东特别大会上寻求股东批准的特别授权进 行。认购事项所得款项拟用作集团一般营运资金用途；及集团业务发展及扩张(包括但不限于拨付收购 智利采矿权的资金)。 ...

认购事项所得款项总额预计约为1700万港元。扣除相关开支后，认购事项所得款项净额估计约为1670万 港元，相当于净认购价约为每股认购股份0.175港元。认购事项所得款项拟用作集团一般营运资金用途; 及集团业务发展及扩张(包括但不限于拨付收购智利採矿权的资金)。 中国金石(01380)发布公告，于2025年8月22日(交易时段后)，公司分别与六名认购人订立认购协议，据 此，本公司有条件同意配发及发行，而认购人有条件同意认购合共9550.56万股认购股份，认购价为每 股认购股份0.178港元，总代价为1700万港元。 认购股份合共相当于：于公告日期现有已发行股份约25.8%;及紧随完成后经配发及发行认购股份扩大的 已发行股份约20.5%(假设除发行认购股份外已发行股份并无变动)。 ...

经扣除专业费用及其他相关开支后，认购事项的所得款项净额约为7470万港元(按每股认购股份0.03港 元计)，本公司拟将所得款项净额用于偿还本集团流动负债项下的银行贷款及其他借贷;及本集团的一般 营运资金。 智通财经APP讯，北方矿业(00433)发布公告，认购协议所载的所有先决条件已经达成，而认购事项已于 2025年8月18日完成。认购人亦已根据认购协议的条款及条件按每股认购股份0.03港元的认购价合共认 购24.905亿股认购股份。 ...

Group 1 - The company China Antibody-B (03681) announced the issuance of 157 million subscription shares to the subscribers based on the subscription agreement on August 15, 2025 [1]

(产品代码：159732) ★ 跟踪：国证消费电子主题指数 附件 3 验资事项说明 一、基本情况 TCL 科技集团股份有限公司（以下简称贵公司）于 1997 年 7 月 17 日在惠州成立 有限责任公司，2002 年整体变更为股份有限公司，2004 年 1 月于深圳证券交易所上市。 本 次 变 更 前 ， 贵 公 司 的 注 册 资 本 为 人 民 币 19,765,372,873 元 ， 股 本 为 人 民 币 二、新增资本的出资规定 根据贵公司 2025 年 3 月 3 日召开的第八届董事会第八次会议，2025 年 3 月 20 日召 开的 2025 年第二次临时股东大会决议通过的《关于公司发行股份及支付现金购买资产 并募集配套资金方案的议案》，贵公司以发行股份及支付现金的方式购买深圳市华星光 电半导体显示技术有限公司（以下简称"标的公司"）股东深圳市重大产业发展一期基金 有限公司（以下简称"重大产业基金"）所持的标的公司 21.5311%股权。根据中国证券监 督管理委员会批复的《关于同意 TCL 科技集团股份有限公司发行股份购买资产并募集 配套资金注册的批复》（证监许可〔2025〕1326 号），同意贵 ...

第四范式(06682)发布公告，配售协议所载的先决条件及所有条件已获达成，而完成根据认购协议的条 款于2025年8月14日落实。根据认购协议的条款及条件，合共2590万股认购股份已按认购价每股认购股 份50.50港元向认购人配发及发行，相当于紧接完成前已发行H股数目约8.78%及已发行股份数目约 5.25%;及经配发及发行认购股份所扩大的已发行H股数目约8.07%及已发行股份数目约4.98%。 ...

Group 1 - North Sea Kangcheng-B signed a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at HKD 1.34 per share, representing a discount of approximately 19.76% compared to the previous trading day's closing price [2] - The subscription is expected to raise HKD 100 million, with net proceeds estimated at approximately HKD 98.6618 million, which will be used for product research and development, marketing promotion, loan repayment, and daily operations [2] - The company's shares will be suspended from trading starting at 9:00 AM on August 12, 2025, and will resume trading at 9:00 AM on August 13, 2025 [2]

Core Viewpoint - The company, 北海康成-B (01228), has entered into a subscription agreement with 百洋健康产业国际商贸有限公司 to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription are intended to be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) general operational activities of the group [1] - Trading of the company's shares was suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the request of the company, pending the announcement [1]